Nov 20, 2019 | METH in the news
Meth-related overdose fatalities have significantly outpaced other drug overdose deaths in the the past five years. But has anyone noticed? Source: Meth Deaths Soar in Hawaii Even As Opioids Grab Public...
Nov 20, 2019 | METH in the news, Uncategorized
Source: Meth in the Miami Valley: Drug coming back more addictive, powerful
Aug 12, 2019 | Anti-METH antibody, IXT-m200, General News
InterveXion Therapeutics, a private clinical-stage biopharmaceutical company developing immunotherapies for substance abuse disorders, today announced the expansion of its international intellectual property estate with the allowance of a key patent in Japan. In July...
Jul 29, 2019 | Anti-METH antibody, IXT-m200, General News, METH in the news
IXT-m200 produced immediate, dose-dependent, time-dependent changes in primary endpoint parameters of methamphetamine AUC and Cmax LITTLE ROCK, AR, USA, July 29, 2019 — InterveXion Therapeutics, a private clinical-stage biopharmaceutical company developing...
Jul 25, 2019 | METH in the news
Source: Asia’s meth trade is now worth an estimated $61B … with no end to the crisis in sight – CNN
Jun 24, 2019 | METH in the news
Experts warn meth is cheap, pure and lethal. In 2009, 50 people died in meth-related incidents; in 2018 that number was 272. Source: Meth-related deaths surge in Oregon |...
Jun 24, 2019 | METH in the news
Meth In The Morning, Heroin At Night: Inside The Seesaw Struggle of Dual Addiction Source: Meth Plus Opioids: New Hazards Of Dual Addiction : Shots – Health News :...
May 22, 2019 | METH in the news
…about half of people who experience a mental illness will also experience a substance use disorder at some point in their lives and vice versa. Source: DrugFacts: Comorbidity: Substance Use Disorders and Other Mental Illnesses | National Institute on Drug Abuse...
May 20, 2019 | General News
Little Rock, AR (20 May 2019) – InterveXion Therapeutics, a private clinical-stage biopharmaceutical company focused on developing immunotherapies for substance abuse disorders, today announced that its Board of Managers has appointed Keith W. Ward, Ph.D., to serve as...
May 13, 2019 | General News
Little Rock, AR (13 May 2019) – InterveXion Therapeutics, a private clinical-stage biopharmaceutical company focused on developing immunotherapies for substance abuse disorders, today announced an expansion to its Executive Leadership Team that strengthens the team...
Recent Comments